Baseline characteristics of patients treated with rosiglitazone and other oral hypoglycaemic agents from 1 January 2000 to 31 December 2010 in northern Denmark and the UK
| Characteristic | Northern Denmark (n=67 525) | UK (n=191 276) | ||
|---|---|---|---|---|
| Users of rosiglitazone (n=2321) N (%) | Users of other oral hypoglycaemic agents (n=65 204) N (%) | Users of rosiglitazone (n=25 428) N (%) | Users of other oral hypoglycaemic agents (n=165 848) N (%) | |
| Age group (years) | ||||
| <35 | 83 (3.6) | 3999 (6.1) | 589 (2.3) | 9358 (5.6) |
| 35–44 | 286 (12) | 4967 (7.6) | 2469 (9.7) | 13 192 (8.0) |
| 45–54 | 595 (26) | 10 219 (16) | 5513 (22) | 25 023 (15) |
| 55–64 | 757 (33) | 16 751 (26) | 7661 (30) | 38 668 (23) |
| 65–74 | 444 (19) | 15 724 (24) | 6434 (25) | 42 030 (25) |
| 75–84 | 147 (6.3) | 10 423 (16) | 2426 (9.5) | 28 430 (17) |
| ≥85 | 9 (0.39) | 3121 (4.8) | 336 (1.3) | 9147 (5.5) |
| Sex | ||||
| Female | 976 (42) | 30 845 (47) | 11 259 (44) | 78 772 (48) |
| Male | 1345 (58) | 34 359 (53) | 14 169 (56) | 87 076 (53) |
| Charlson comorbidity index | ||||
| 0 | 1694 (73) | 41 183 (63) | 16 646 (65) | 95 607 (58) |
| 1–2 | 561 (24) | 19 470 (30) | 7925 (31) | 57 984 (35) |
| 3+ | 66 (2.8) | 4551 (7.0) | 857 (3.4) | 12 257 (7.4) |
| History of OHA use before baseline* | ||||
| Metformin | 2279 (98) | 51 022 (78) | 23 836 (94) | 144 881 (87) |
| Sulfonylurea | 1730 (74) | 39 931 (61) | 19 489 (77) | 90 682 (55) |
| Pioglitazone | 81 (3.5) | 196 (0.30) | 9297 (37) | 14 194 (8.6) |
| DPP 4 inhibitor | 517 (22) | 4149 (6.4) | 2242 (8.8) | 5882 (3.6) |
| Other oral glucose-lowering drugs† | 497 (21) | 5530 (8.5) | 2582 (10) | 5725 (3.5) |
| History of other medication use | ||||
| Lipid-lowering agents | 1939 (84) | 40 327 (62) | 22 223 (87) | 114 378 (69) |
| Antihypertensive agents | 1991 (86) | 48 016 (74) | 21 846 (86) | 126 897 (77) |
| Diuretics | 1404 (60) | 34 650 (53) | 13 516 (53) | 73 225 (44) |
| Nitrates | 351 (15) | 9456 (14) | 52 (0.20) | 322 (0.19) |
| Antiplatelet agents | 1409 (61) | 33 060 (51) | 2878 (11) | 15 223 (9.2) |
| Smoking | ||||
| Current | 175 (7.5) | 2451 (3.8) | 4499 (18) | 28 120 (17) |
| Former | 215 (9.3) | 3121 (4.8) | 6102 (24) | 43 985 (27) |
| Never | 258 (11) | 3534 (5.4) | 11 699 (46) | 75 119 (45) |
| Missing | 1673 (72) | 56 098 (86) | 3128 (12) | 18 624 (11) |
| Body mass index category (kg/m2) | ||||
| <18.5 | 2 (0.09) | 32 (0.05) | 35 (0.14) | 623 (0.38) |
| 18.5–<25 | 51 (2.2) | 1257 (1.9) | 2675 (11) | 21 634 (13) |
| 25–<30 | 177 (7.6) | 3257 (5.0) | 7458 (29) | 49 463 (30) |
| ≥30 | 462 (20) | 5454 (8.4) | 11 225 (44) | 66 725 (40) |
| Missing | 1629 (70) | 55 204 (85) | 4035 (16) | 27 403 (17) |
*Baseline date was 1 January 2000 or date of first OHA prescription, whichever came later.
†Other glucose-lowering drugs excluding insulins are acarbose, repaglinide, exenatide and liraglutide.
OHA, oral hypoglycaemic agent.